Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Metagenomi
AddedFeb 13, 2024
UpdatedJul 5, 2026
Metagenomi

Metagenomi

Metagenomi: Pioneering next-gen gene-editing systems to treat genetic diseases.

HQ
Emeryville, CA, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Metagenomi, founded by pioneers in the CRISPR/CAS revolution, is dedicated to discovering and developing next-generation gene-editing systems aimed at treating genetic diseases. The company leverages metagenomics, the study of genomes recovered from uncultivated organisms in natural environments, to create potentially curative therapeutics. Metagenomi's innovative genome-editing toolbox aims to surpass current technological capabilities, offering precise and versatile therapeutic gene edits across the human genome.

Notable figures affiliated with Metagenomi include its founding scientists who have significantly contributed to advancements in CRISPR technology. The company has attracted substantial investment from leading biotech investors, enabling rapid progress in its research and development efforts. Metagenomi's breakthroughs in gene-editing tools have positioned it as a key player in the field of genetic medicine, with the potential to revolutionize treatments for a wide range of genetic disorders.

Metagenomi - Similar Companies

Emendo Biotherapeutics logo

Emendo Biotherapeutics

emendobio.com

Acrigen Biosciences logo

Acrigen Biosciences

acrigen.com

Editas Medicine logo

Editas Medicine

GenEdit logo

GenEdit

genedit.com

Mammoth Biosciences logo

Mammoth Biosciences

Arbor Biotechnologies logo

Arbor Biotechnologies

arbor.bio

Epic-Bio logo

Epic-Bio

epic-bio.com

Tome Biosciences logo

Tome Biosciences

tome.bio

Amber Bio logo

Amber Bio

amber.bio

GeneTether logo

GeneTether

genetether.com

Caribou Biosciences logo

Caribou Biosciences

cariboubio.com

Intellia Therapeutics logo

Intellia Therapeutics

intelliatx.com

Synthego logo

Synthego

synthego.com

Hunterian Medicine logo

Hunterian Medicine

hunterian.com

Inscripta logo

Inscripta

inscripta.com

Metagenomi - Quick Facts

Who are Metagenomi's competitors?

Companies similar to Metagenomi include Emendo Biotherapeutics, Acrigen Biosciences, Editas Medicine and GenEdit.

When was Metagenomi founded?

Metagenomi was founded in 2016.

Where is Metagenomi's headquarters located?

Metagenomi's headquarters is located in Emeryville, CA, US.

When was Metagenomi's last funding round?

Metagenomi's most recent funding round was for $100M (USD) in January 2023.

How much has Metagenomi raised to-date?

As of Jan 5, 2023, Metagenomi has raised a total of $457M (USD).

How many employees does Metagenomi have?

Metagenomi has 191 employees as of Feb 4, 2024.

Metagenomi - Classification

Industry
  • Therapeutics
Ownership
  • Private Equity
  • Venture Capital
Technology
  • Biotech
  • GenAI
Geographic Exposure
  • Global
Main Product
  • Gene Editing
Tags
  • Biotech
Unique IDs
  • secCik: 0001785279
  • ticker: MGX
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software